Quest PharmaTech Stock Surges 128.6% in 2026 on Cancer Therapy Pipeline

Quest PharmaTech Inc. (QPTFF) has delivered a remarkable 128.6% year-to-date gain, trading at $0.0304 per share on the pink sheets market. The Edmonton-based biotech company is advancing a focused pipeline of antibody-based immunotherapeutic products targeting cancer. Its lead candidate, Mab AR 9.6, targets truncated O-glycan on MUC16 for precision cancer therapy. The company also progresses Oregovomab, an anti-CA-125 antibody that completed Phase II trials for ovarian cancer treatment. With earnings scheduled for May 28, 2026, investors are watching QPTFF stock closely as the company pursues clinical validation and commercialization of its immunotherapy platform.

QPTFF Stock Performance and Trading Activity

QPTFF stock has demonstrated exceptional strength in 2026, climbing 128.6% year-to-date from its January lows. The stock trades at $0.0304 per share with a market capitalization of $5.14 million USD. Trading volume surged to 225,625 shares, representing a relative volume spike of 112,812.5x versus the typical daily average of just 2 shares. This dramatic volume increase signals renewed investor interest in the biotech’s clinical progress.

The stock’s 50-day moving average sits at $0.0256, while the 200-day average stands at $0.0164, indicating sustained upward momentum. The year-to-date range spans from a low of $0.0133 to a high of $0.04, reflecting volatility typical of early-stage biotech companies. Track QPTFF on Meyka for real-time updates on trading activity and price movements.

Cancer Immunotherapy Pipeline Driving Growth

Quest PharmaTech’s clinical pipeline centers on monoclonal antibody therapies designed to target cancer-specific antigens. The company’s lead program, Mab AR 9.6, represents a novel approach to precision oncology by targeting truncated O-glycan structures on MUC16, a tumor-associated antigen overexpressed in multiple cancer types.

Oregovomab, the company’s second major asset, is an anti-CA-125 antibody that has advanced through Phase II clinical trials for ovarian cancer treatment. This program builds on established clinical data and represents a validated therapeutic approach. The company also develops combinatorial immunotherapeutic products using monoclonal antibodies of the immunoglobulin G and E classes, expanding its therapeutic options for cancer patients across multiple indications.

Financial Position and Valuation Metrics

Quest PharmaTech operates with a lean balance sheet typical of clinical-stage biotech companies. The company reported a market cap of $5.14 million USD with 169.1 million shares outstanding. Book value per share stands at $0.1365, giving the stock a price-to-book ratio of just 0.31x, suggesting potential undervaluation relative to tangible assets.

The company carries minimal debt with a debt-to-equity ratio of 0.043, indicating conservative financial management. However, QPTFF is pre-revenue with negative earnings of $0.01 per share, reflecting typical biotech development costs. Operating cash flow per share is $0.0002, while free cash flow per share matches this figure, showing the company is burning through cash reserves to fund clinical development.

Market Sentiment and Technical Indicators

Technical analysis reveals extreme overbought conditions with an RSI reading of 100.0, indicating potential pullback risk in the near term. The ADX trend indicator also reads 100.0, confirming a strong directional trend despite the overbought status. The Stochastic Momentum Index (SMI) registers 100.0, reinforcing the intensity of recent buying pressure.

On-balance volume (OBV) totals 225,625 shares, reflecting the volume spike that accompanied recent price appreciation. The Money Flow Index (MFI) sits at 50.0, suggesting neutral money flow dynamics despite the price surge. These technical extremes warrant caution, as mean reversion could occur following such extended rallies in low-liquidity pink sheet stocks.

Final Thoughts

Quest PharmaTech Inc. (QPTFF) has captured investor attention with its 128.6% year-to-date surge and dramatic volume spike to 225,625 shares. The company’s focused pipeline of cancer immunotherapies, led by Mab AR 9.6 and Oregovomab, represents meaningful clinical progress in precision oncology. Trading at $0.0304 per share with a price-to-book ratio of just 0.31x, the stock appears undervalued on a tangible asset basis. However, extreme technical overbought conditions (RSI 100.0) and the company’s pre-revenue status warrant careful consideration. Meyka AI rates QPTFF with a grade of B, suggesting a HOLD stance. Investors should await the May 28 earnings announcement a…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.